New Research Validating VeraBIND™ Tau Assay as Accurate Blood Test for Active Tau Pathology in Alzheimer’s Disease Presented at the 2025 Alzheimer’s Association International Conference featuring Veravas Inc.
Developed by Veravas Inc., VeraBIND™ Tau Assay is the first blood-based test that measures pathologically active tau for the early detection of Alzheimer’s disease in both asymptomatic and symptomatic individuals
AUSTIN, Texas, July 28, 2025 /PRNewswire/ — Veravas Inc., an innovator in diagnostics dedicated to advancing health outcomes through early disease detection, announced that two independent analyses, presented at the 2025 Alzheimer’s Association International Conference (AAIC), demonstrate that the VeraBIND Tau assay accurately measures active tau pathology—a key biomarker of Alzheimer’s disease (AD) and other tauopathies—in individuals with and without cognitive impairment.
Unlike currently available tests that quantify biomarker levels, the VeraBIND Tau assay measures the pathological binding activity between hyperphosphorylated tau and normal tau—a hallmark of AD noting the active spread of tau proteins—which provides a more direct measure of disease activity, that can be observed years before AD symptoms may appear. Assessing the level of binding activity as an indicator of the potential spread of hyperphosphorylated tau provides a more accurate and sensitive diagnostic approach, adding an important layer of understanding in the pathological progression of disease. The VeraBIND Tau assay is a blood-based test that detects tau pathology in adult patients aged 50 years and older, and produces results consistent with tau positron emission tomography (Tau-PET) brain scans.
